iBio Announces $50 Million Public Offering Agreement

Ibio ( (IBIO) ) has issued an update.

On August 19, 2025, iBio, Inc. announced an underwriting agreement with Leerink Partners LLC for a public offering involving pre-funded warrants and Series G and H warrants to purchase shares of common stock. The offering, expected to raise approximately $50 million, aims to advance iBio’s preclinical cardiometabolic programs and other pipeline assets. The company has agreed to certain restrictions on stock issuance and sale for 90 days following the offering’s pricing. The offering’s completion is subject to customary closing conditions, with the closing expected around August 22, 2025.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.

IBIO’s overall score is heavily impacted by significant financial challenges, including negative earnings and cash flow issues. The weak technical outlook and poor valuation metrics further weigh down the score. However, recent strategic corporate events provide some optimism for future growth, but they are not enough to offset the current financial difficulties.

To see Spark’s full report on IBIO stock, click here.

More about Ibio

iBio, Inc. is a biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases. The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments addressing significant unmet medical needs.

Average Trading Volume: 2,085,691

Technical Sentiment Signal: Sell

Current Market Cap: $11.89M

Find detailed analytics on IBIO stock on TipRanks’ Stock Analysis page.